The Medicines Patent Pool participated in AIDS 2024, the 25th International AIDS Conference in Munich, Germany and virtually from 22-26 July, as well as the pre-conference on 20 and 21 July. MPP shared a booth (#904) with Unitaid in the exhibition area.
AIDS 2024 convened thousands of people living with, affected by and working on HIV to share knowledge, best practices and lessons learnt from the HIV response over the past 40 years, as well as from the responses to COVID-19, mpox and other public health threats.
AIDS 2024 in Munich, Germany, and virtually provided a powerful platform to strategically align around a unified and equitable response to the pandemic. It signaed to the world that the HIV response is united behind an evidence-based approach that puts people first.
MPP colleagues actively participated in a number of sessions:
Saturday, 20 July, 8:00 – 9:00 | Room 14a / Channel 9 The PrEP product introduction landscape Pre-conference session (session 1) Esteban Burrone, Director, Policy, Strategy and Market Access, speaking as a panellist More information
Monday, 22 July, 11:30 – 12:30 | Room 14a/Channel 9 Lessons learned from the DTG story MPP/Unitaid satellite session Esteban Burrone, Director, Policy, Strategy and Market Access, providing closing remarks More information
Tuesday, 23 July, 10:30 – 11:30 | Room 13b/Channel 7 The law, human rights and access to medicines Oral abstract session | Track F: Political science, laws, ethics, policies and human rights Mila Maistat, Senior Manager, Policy, Strategy and Market Access, providing introductory remarks More information
Wednesday, 24 July, 18:00 – 19:30 | Hall B0a/Channel 4 An action plan to accelerate bNAbs for peri- and post-natal prophylaxis (PNP) IAS, IAVI, Desmond Tutu Health Foundation satellite session Sébastien Morin, Senior Manager, Policy, Strategy and Market Access, speaking as a panellist More information
Friday, 26 July, 10:30 – 11:30 | Room 1/Channel 2 No retreat! No surrender! The urgency of aligning investments where they are needed the most in the global HIV response Symposium | Track E: Implementation science, economics, systems and synergies Lobna Gaayeb, Head of Scientific and Medical Affairs, moderating the session More information
Friday, 26 July, 12:00 – 13:00 | Room 13b/Channel 7 Taking Action on Long-Acting Injectable PrEP: Towards access and implementation Symposium | Track E: Implementation science, economics, systems and synergies Esteban Burrone, Director, Policy, Strategy and Market, moderating the session More information
MPP shared a booth (#904) with Unitaid in the exhibition area.
Tuesday, 23 July, 11:30 – 12:00 | AVAC’s Research Literacy Zone at the Global Village (booth HT0401) Process and considerations for generics licensing with MPP Session organised by AVAC in collaboration with CS Caucus of LA PrEP Coalition Sébastien Morin, Senior Manager, Policy, Strategy and Market Access, presenting
Tuesday, 23 July, 14:00 – 14:50 | PLHIV Networking Zone at the Global Village #BetterMeds4Kids – Children’s Access to Life-Saving HIV Treatment Session organised by GNP+ and PATA Sébastien Morin, Senior Manager, Policy, Strategy and Market Access, presenting
Wednesday, 24 July, 9:45 – 10:45 | Booth of France in the Exhibition Area (#804) Accès équitable aux traitements et innovations contre le VIH : regards croisés sur les leçons apprises et défis à venir Session organised by France, moderated by Anne-Claire Amprou, French Ambassador for Global Health Esteban Burrone, Director, Policy, Strategy and Market, speaking
Wednesday, 24 July, 11:30 – 12:30 | Booth of MPP and Unitaid in the Exhibition Area (#904) Direct from the Source: The DTG Film Story Session organised by MPP – download flyer > Step behind the lens and experience the making of the “I am part of the DTG story” film. Meet and converse with the community heroes who shared their powerful stories during the cinema premiere at the World Health Assembly. Join us at the MPP booth for this enlightening session Watch the recording: YouTube live
Wednesday, 24 July, 13:15 – 14:00 | Booth of MPP and Unitaid in the Exhibition Area (#904) #BetterMeds4Kids: Accelerating access to better HIV medicines for children Session organised by MPP and partners of the Global Accelerator for Paediatric Formulations (GAP-f) WHO network – download flyer > Children are one of the most vulnerable yet neglected populations in terms of access to optimal medicines in adapted formulations. Consequently, paediatric therapies often remain limited and sub-optimal. Hear from partners of the Global Accelerator for Paediatric Formulations (GAP-f) WHO network, of which MPP is a founding member, as they share their experiences in addressing innovation and access challenges in developing and improving access to HIV medicines for children. Watch the recording: YouTube live
Thursday, 25 July, 11:00 – 12:00 | Booth of MPP and Unitaid in the Exhibition Area (#904) NAVIGATING LONG-ACTING THERAPEUTICS: LAPaL, a database at the Intersection of Innovation and Access Session organised by MPP – download flyer > LAPaL is the only online open access tool dedicated to supporting access to long-acting therapeutics. It not only provides patent and licensing information about key long-acting technologies and compounds, but also captures clinical development, regulatory filing information of selected treatment and prevention medicines. LAPaL aim is to provide reliable information and support innovation in the long-acting therapeutics while fostering access. Join this hands-on session to discover it! If possible, come with your computer/tablet to get the full experience!
Press and Media
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to and facilitate the development of life-saving medicines for low- and middle-income countries. Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups, and other stakeholders to prioritise and license needed medicines and pool intellectual property to encourage generic manufacture and the development of new formulations.
To date, MPP has signed agreements with 22 patent holders for 13 HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals, a tuberculosis treatment, a cancer treatment, four long-acting technologies, a post-partum haemorrhage medicine, three oral antiviral treatments for COVID-19 and 16 COVID-19 technologies.
MPP was founded by Unitaid, which continues to be MPP’s main funder. MPP’s work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC), Government of Canada, the World Intellectual Property Organization (WIPO) and the Government of Flanders. MPP’s activities in COVID-19 are undertaken with the financial support of the Japanese Government, the French Ministry for Europe and Foreign Affairs, the German Agency for International Cooperation, and SDC.